KGML-xDTD: a knowledge graph–based machine learning framework for drug treatment prediction and mechanism description

Author:

Ma Chunyu1ORCID,Zhou Zhihan2ORCID,Liu Han2,Koslicki David134ORCID

Affiliation:

1. Huck Institutes of Life Sciences, Pennsylvania State University , State College, PA 16801 , USA

2. Department of Computer Science, Northwestern University , Evanston, IL 60208 , USA

3. Department of Computer Science and Engineering, Pennsylvania State University , State College, PA 16801 , USA

4. Department of Biology, Pennsylvania State University , State College, PA 16801 , USA

Abstract

Abstract Background Computational drug repurposing is a cost- and time-efficient approach that aims to identify new therapeutic targets or diseases (indications) of existing drugs/compounds. It is especially critical for emerging and/or orphan diseases due to its cheaper investment and shorter research cycle compared with traditional wet-lab drug discovery approaches. However, the underlying mechanisms of action (MOAs) between repurposed drugs and their target diseases remain largely unknown, which is still a main obstacle for computational drug repurposing methods to be widely adopted in clinical settings. Results In this work, we propose KGML-xDTD: a Knowledge Graph–based Machine Learning framework for explainably predicting Drugs Treating Diseases. It is a 2-module framework that not only predicts the treatment probabilities between drugs/compounds and diseases but also biologically explains them via knowledge graph (KG) path-based, testable MOAs. We leverage knowledge-and-publication–based information to extract biologically meaningful “demonstration paths” as the intermediate guidance in the Graph-based Reinforcement Learning (GRL) path-finding process. Comprehensive experiments and case study analyses show that the proposed framework can achieve state-of-the-art performance in both predictions of drug repurposing and recapitulation of human-curated drug MOA paths. Conclusions KGML-xDTD is the first model framework that can offer KG path explanations for drug repurposing predictions by leveraging the combination of prediction outcomes and existing biological knowledge and publications. We believe it can effectively reduce “black-box” concerns and increase prediction confidence for drug repurposing based on predicted path-based explanations and further accelerate the process of drug discovery for emerging diseases.

Funder

National Institutes of Health

National Science Foundation

Publisher

Oxford University Press (OUP)

Subject

Computer Science Applications,Health Informatics

Reference94 articles.

1. An overview of drug discovery and development;Berdigaliyev;Future Med Chem,2020

2. Thalidomide embryopathy: a model for the study of congenital incomitant horizontal strabismus;Miller;Trans Am Ophthalmol Soc,1991

3. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits;Verheul;Br J Cancer,1999

4. Antitumor activity of thalidomide in refractory multiple myeloma;Singhal;N Engl J Med,1999

5. Binding affinity in drug design: experimental and computational techniques;Kairys;Expert Opin Drug Discov,2019

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3